EUVIMEDDescoperă EUVIMED
Open access · CC BY-NC-ND 4.0

Applying DanGer Shock Eligibility Criteria to a Real‐World Cohort of Cardiogenic Shock Patients

Raffaela Miriam Planka iD, Lukas Herold iD, Theresa Glantschnig, Gudrun Sommer, Jonathan Pavek, Stefan Hatzl iD, Nicolas Verheyen iD, Christoph Strohhofer, Johannes Gollmer, Ewald Kolesnik iD, Martin Benedikt, Markus Wallner and 3 more

Catheterization and Cardiovascular Interventions · 2025

DOI: 10.1002/ccd.70239 ↗

At a glance

Journal article in Catheterization and Cardiovascular Interventions, 2025. Written by Raffaela Miriam Planka and 14 co-authors. Institution: Department of Internal Medicine, Division of Cardiology, Medical University of Graz, Graz, Austria. Major MEDLINE topics: Shock, Cardiogenic, ST Elevation Myocardial Infarction, Eligibility Determination, Cardiac Catheterization. 31 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: The authors received no specific funding for this work..

RezumatSubjectsDate bibliograficeCiteRelated studies

Abstract (original language)

Background

The DanGer Shock trial investigated the effects of adding a microaxial flow pump to guideline‐recommended therapy in patients with ST‐elevation myocardial infarction (STEMI)‐related cardiogenic shock (CS), finding a lower all‐cause mortality at 180 days in the intervention group.

Methods

DanGer Shock eligibility criteria were applied to the prospective single‐center PREPARE CardShock registry, which consecutively enrolled 721 patients between April 2019 and August 2024 with advanced CS—classified as stages C to E according to the SCAI shock classification—who were on vasoactive medication and underwent cardiac catheterization.

Results

Among 721 patients in the registry, 384 (53.3%) had STEMI‐related CS. Of those, 117 (30.5%) met DanGer Shock trial eligibility criteria, accounting for 16.2% of the registry cohort. Median age of the eligible patients was 68 years (interquartile range [IQR]: 58–78), and 62.4% were male, compared to 68 years (IQR: 60–76) and 79.2% in DanGer Shock. PREPRARE‐CS DanGer Shock eligible patients had a higher median systolic blood pressure (SBP) (92 mmHG [78–107] vs. 83 mmHG, [72–91]) and higher median lactate levels (5.2 mmol/L [3.6–7.6] vs. 4.6 mmol/L [3.3–7.0]) at baseline, and were more frequently resuscitated (56.4% vs. 20.3%). Device use was 42.7% in eligible patients. Renal replacement therapy (RRT) was more frequent among trial participants (34.4% vs. 17.1%). The 180‐day mortality rate among eligible patients was 71.8%, compared to 52.1% in trial participants.

Conclusions

Among STEMI‐related CS patients in our cohort, only one‐third met the DanGer Shock eligibility criteria. Consequently, trial outcomes may not be broadly applicable.

Subjects

MeSH terms (MEDLINE)

Shock, CardiogenicST Elevation Myocardial InfarctionEligibility DeterminationCardiac CatheterizationPercutaneous Coronary InterventionHumansMaleFemaleAgedMiddle AgedRegistriesTime FactorsTreatment OutcomeProspective StudiesRisk FactorsRisk AssessmentPatient Selection

Author keywords

AMICSMCSSTEMI‐related CScardiogenic shockmicroaxial flow pumpmortality

Authors and institutions

  • Department of Internal Medicine, Division of Cardiology, Medical University of Graz, Graz, Austria.
  • Karl Landsteiner University of Health Science, Krems, Austria.
  • Intensive Care Unit, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
  • Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Department of Cardiology, Public Hospital Klagenfurt, Klagenfurt, Austria.

ORCID profiles: Raffaela Miriam Planka, Lukas Herold, Stefan Hatzl, Nicolas Verheyen, Ewald Kolesnik

Funding

  • The authors received no specific funding for this work.

Cite

APA

Planka, R. M., Herold, L., Glantschnig, T., Sommer, G., Pavek, J., Hatzl, S., Verheyen, N., Strohhofer, C., Gollmer, J., Kolesnik, E., Benedikt, M., Wallner, M., Zirlik, A., Toth-Gayor, G., & von Lewinski, D. (2025). Applying DanGer Shock Eligibility Criteria to a Real‐World Cohort of Cardiogenic Shock Patients. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.70239

Vancouver

Planka RM, Herold L, Glantschnig T, Sommer G, Pavek J, Hatzl S, et al. Applying DanGer Shock Eligibility Criteria to a Real‐World Cohort of Cardiogenic Shock Patients. Catheterization and Cardiovascular Interventions. 2025. doi:10.1002/ccd.70239

BibTeX
@article{Planka2025,
  author = {Planka, Raffaela Miriam and Herold, Lukas and Glantschnig, Theresa and Sommer, Gudrun and Pavek, Jonathan and Hatzl, Stefan and Verheyen, Nicolas and Strohhofer, Christoph and Gollmer, Johannes and Kolesnik, Ewald and Benedikt, Martin and Wallner, Markus and Zirlik, Andreas and Toth-Gayor, Gabor and von Lewinski, Dirk},
  title = {Applying DanGer Shock Eligibility Criteria to a Real‐World Cohort of Cardiogenic Shock Patients},
  journal = {Catheterization and Cardiovascular Interventions},
  year = {2025},
  doi = {10.1002/ccd.70239}
}
Start for free →